Vimarsana
Biggest News Aggregation in the World

Daniel De Roulet News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daniel De Roulet. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daniel De Roulet Today - Breaking & Trending Today

AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline - Vimarsana News

AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline

/PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage...

AbbVie Exercises Exclusive Right, Completes Acquisition Of Mitokinin - Vimarsana News

AbbVie Exercises Exclusive Right, Completes Acquisition Of Mitokinin

Biopharma major AbbVie Inc. (ABBV) announced on Thursday that it had exercised its exclusive right and completed the acquisition of Mitokinin, a biotechnology company.

AbbVie buys exclusive right to acquire Mitokinin's Parkinson's asset - Vimarsana News

AbbVie buys exclusive right to acquire Mitokinin's Parkinson's asset

AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset Company can acquire asset following the completion of IND enabling studies AbbVie has purchased an exclusive right to acquire Mitokinin’s lead PINK1 asset following the completion of IND enabling studies for Parkinson’s disease. Mitokinin is based on technology discovered at the University of California, San Francisco (UCSF) by company co-founders Nicholas Hertz and Kevan Shokat. Hertz and Shokat moved the company into MBC BioLabs San Francisco in September 2017 after a series A round led by Mission BioCapital. The ...

Source: pmlive.com
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie - Vimarsana News

Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie

Share this article Share this article SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced today that AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound. Based on technology discovered at UCSF by Mitokinin co-founders Nicholas Hertz and Kevan Shokat, Mitokinin moved into MBC BioLabs San Francisco in September 2017 with Series A fu...